On Friday, Zymeworks BC Inc (NASDAQ: ZYME) opened higher 6.89% from the last session, before settling in for the closing price of $14.08. Price fluctuations for ZYME have ranged from $9.03 to $17.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.81% annually for the last half of the decade. Company’s average yearly earnings per share was noted 38.90% at the time writing. With a float of $72.94 million, this company’s outstanding shares have now reached $74.85 million.
Zymeworks BC Inc (ZYME) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zymeworks BC Inc is 3.69%, while institutional ownership is 101.02%. The most recent insider transaction that took place on May 15 ’25, was worth 565,847. In this transaction Director of this company bought 49,502 shares at a rate of $11.43, taking the stock ownership to the 17,877,989 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,919 for $11.78, making the entire transaction worth $69,738. This insider now owns 17,883,908 shares in total.
Zymeworks BC Inc (ZYME) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.39 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.41) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 38.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.56% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Check out the current performance indicators for Zymeworks BC Inc (ZYME). In the past quarter, the stock posted a quick ratio of 7.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Let’s dig in a bit further. During the last 5-days, its volume was 0.54 million. That was better than the volume of 0.53 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.72%.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 92.96%, which indicates a significant increase from 82.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.61 in the past 14 days, which was higher than the 0.58 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.58, while its 200-day Moving Average is $13.16. However, in the short run, Zymeworks BC Inc’s stock first resistance to watch stands at $15.53. Second resistance stands at $16.02. The third major resistance level sits at $16.75. If the price goes on to break the first support level at $14.31, it is likely to go to the next support level at $13.58. Assuming the price breaks the second support level, the third support level stands at $13.09.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
There are currently 75,166K shares outstanding in the company with a market cap of 1.14 billion. Presently, the company’s annual sales total 76,300 K according to its annual income of -122,700 K. Last quarter, the company’s sales amounted to 48,730 K and its income totaled 2,320 K.
